相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas
Melinda Varadi et al.
CANCER MEDICINE (2023)
Drugging p53 in cancer: one protein, many targets
Ori Hassin et al.
NATURE REVIEWS DRUG DISCOVERY (2023)
Immune Microenvironment Characteristics of Urachal Carcinoma and Its Implications for Prognosis and Immunotherapy
Xinke Zhang et al.
CANCERS (2022)
Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma An Analysis of 30 Cases by Next-Generation Sequencing
Michael P. Zaleski et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2022)
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
J. H. Strickler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
Clelia Madeddu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice
Davide Loizzo et al.
EUROPEAN UROLOGY OPEN SCIENCE (2022)
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Jiahao Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Gongmin Zhu et al.
MOLECULAR CANCER (2021)
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab et al.
MOLECULES (2021)
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
Kan Yonemori et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
Precision Therapy in RAS Mutant Colorectal Cancer
Rodrigo Dienstmann et al.
GASTROENTEROLOGY (2020)
Comparative genomic profiling of glandular bladder tumours
Angela Maurer et al.
VIRCHOWS ARCHIV (2020)
TargetingKRASMutant Non-Small-Cell Lung Cancer: Past, Present and Future
Iris Z. Uras et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prevalence of APC and PTEN Alterations in Urachal Cancer
Nikolett Nagy et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
Kohei Shitara et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib
Tiffany Seto et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Next-generation sequencing-based molecular analysis of urachal adenocarcinomas
N. Nagy et al.
EUROPEAN UROLOGY SUPPLEMENTS (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Markus Eckstein et al.
EUROPEAN JOURNAL OF CANCER (2019)
Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis
Giulio Riva et al.
VIRCHOWS ARCHIV (2019)
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
Yingyan Yu
FRONTIERS OF MEDICINE (2018)
MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma
Meng Zhang et al.
HUMAN PATHOLOGY (2018)
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
Henning Reis et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
USCAP 2018 Abstracts: Genitourinary Pathology (894–1126)
LABORATORY INVESTIGATION (2018)
Molecular and therapeutic aspects of advanced urachal cancer
O. Modos et al.
EUROPEAN UROLOGY SUPPLEMENTS (2017)
Comprehensive somatic genome alterations of urachal carcinoma
Seungchul Lee et al.
JOURNAL OF MEDICAL GENETICS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma
Jen-Fan Hang et al.
PATHOLOGY (2017)
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype
Jordan Kardos et al.
JCO PRECISION ONCOLOGY (2017)
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
Soojin Cha et al.
BMC CANCER (2016)
Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma
Kah Poh Loh et al.
CLINICAL GENITOURINARY CANCER (2016)
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
Ana Collazo-Lorduy et al.
EUROPEAN UROLOGY (2016)
MUTATIONAL LANDSCAPE OF PRIMARY BLADDER AND URACHAL ADENOCARCINOMA
Byron Lee et al.
JOURNAL OF UROLOGY (2016)
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases
Tibor Szarvas et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations
Harshabad Singh et al.
ONCOTARGET (2016)
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance
Orsolya Modos et al.
ONCOTARGET (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance
M. Dietel et al.
CANCER GENE THERAPY (2015)
Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma
E. Jordan et al.
EUROPEAN JOURNAL OF CANCER (2015)
MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
Paolo Luraghi et al.
CANCER RESEARCH (2014)
High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations
S. Joseph Sirintrapun et al.
HUMAN PATHOLOGY (2014)
Response to targeted therapy in urachal adenocarcinoma
Isabella Testa et al.
RARE TUMORS (2014)
PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer
Fiona L. Day et al.
CLINICAL CANCER RESEARCH (2013)
Targeted cancer therapy - Are the days of systemic chemotherapy numbered?
Won Duk Joo et al.
MATURITAS (2013)
The Clinical Epidemiology of Urachal Carcinoma: Results of a Large, Population Based Study
H. Max Bruins et al.
JOURNAL OF UROLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Quality Assessment and Correlation of Microsatellite Instability and Immunohistochemical Markers among Population- and Clinic-Based Colorectal Tumors Results from the Colon Cancer Family Registry
Mine S. Cicek et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Hanlin L. Wang et al.
ADVANCES IN ANATOMIC PATHOLOGY (2010)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
G Goss et al.
INVESTIGATIONAL NEW DRUGS (2005)
分享论文
